Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Lung Neoplasms 1

Interventions

Carboplatin 202pembrolizumab 166Pemetrexed 140Cisplatin 124Paclitaxel 77durvalumab 74osimertinib 69Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 57Magnetic Resonance Spectroscopy 53Etoposide 47Gemcitabine 46Radiotherapy 43Radiosurgery 40130-nm albumin-bound paclitaxel 34Drug Therapy 32Bevacizumab 29Ipilimumab 28Cetuximab 27cemiplimab 25Taxes 24tislelizumab 21Immunoglobulin G 21Platinum 20Biopsy 20amivantamab 19Radiation 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sugemalimab × Thoracic × 90 days × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡